ClearPoint Neuro (CLPT)
(Delayed Data from NSDQ)
$10.81 USD
-0.40 (-3.57%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $10.82 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Income Statements
Fiscal Year end for ClearPoint Neuro, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 24 | 21 | 16 | 13 | 11 |
Cost Of Goods | 10 | 7 | 5 | 4 | 4 |
Gross Profit | 14 | 14 | 11 | 9 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 36 | 30 | 25 | 15 | 12 |
Income After Depreciation & Amortization | -22 | -16 | -13 | -6 | -5 |
Non-Operating Income | 0 | 0 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 1 | 1 | 1 |
Pretax Income | -22 | -16 | -14 | -7 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -22 | -16 | -14 | -7 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -22 | -16 | -14 | -7 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -16 | -13 | -5 | -4 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -22 | -16 | -13 | -6 | -5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 24.61 | 24.18 | 20.73 | 15.85 | 13.16 |
Diluted EPS Before Non-Recurring Items | -0.90 | -0.68 | -0.69 | -0.43 | -0.42 |
Diluted Net EPS (GAAP) | -0.90 | -0.68 | -0.69 | -0.43 | -0.42 |
Fiscal Year end for ClearPoint Neuro, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 7.86 | 7.64 | 6.81 | 5.76 | 5.95 |
Cost Of Goods | 2.87 | 3.11 | 2.80 | 2.49 | 2.82 |
Gross Profit | 4.99 | 4.53 | 4.01 | 3.27 | 3.13 |
SG&A, R&D, and Dept/Amort Expenses | 9.73 | 8.76 | 8.72 | 8.17 | 10.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.74 | -4.23 | -4.71 | -4.90 | -7.13 |
Non-Operating Income | 0.33 | 0.09 | 0.00 | 0.09 | 0.08 |
Interest Expense | 0.00 | 0.00 | -0.39 | 0.00 | 0.00 |
Pretax Income | -4.41 | -4.15 | -4.62 | -4.81 | -7.05 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.41 | -4.15 | -4.62 | -4.81 | -7.05 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.41 | -4.15 | -4.62 | -4.81 | -7.05 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 27.47 | 25.45 | 24.61 | 24.63 | 24.58 |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.16 | -0.19 | -0.20 | -0.29 |
Diluted Net EPS (GAAP) | -0.16 | -0.16 | -0.18 | -0.20 | -0.29 |